Polaryx Therapeutics
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
140 E Ridgewood Ave Ste 415, Paramus, Ne...Phone Number
(201) 940-7236Website
www.polaryx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Polaryx Therapeutics
Polaryx Therapeutics is a late-stage clinical biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, which are rare inherited metabolic diseases. The company aims to address these conditions through innovative drug candidates that include new chemical entities and repurposed drugs, with a pipeline targeting diseases such as Krabbe, Sandhoff, and Niemann Pick types A and B. Polaryx is committed to creating formulations that ensure high compliance, particularly in pediatric populations, utilizing intranasal and oral delivery methods. Established in 2014, Polaryx Therapeutics operates under experienced leadership dedicated to the safe and effective commercialization of its therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Polaryx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Polaryx Therapeutics has new funding data
Polaryx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Polaryx Therapeutics
Click to see if Polaryx Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Polaryx Therapeutics launches new products
Check if Polaryx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Polaryx Therapeutics recently announced quarterly report
Check out if Polaryx Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Polaryx Therapeutics
Compare insights from companies similar to Polaryx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Polaryx Therapeutics
<$5M
1-10
Private
-
2014
N/A
Company Profile Activity
Activity Insights
Polaryx Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Polaryx Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Polaryx Therapeutics.
Polaryx Therapeutics Tech Stack
A closer look at the technologies used by Polaryx Therapeutics
Most Recent Scoops
Person-Based
Events
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Seeking Replacement
Polaryx Therapeutics News & Media
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award WinnerPolaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Polaryx Therapeutics
Sign Up For FreeTo access detailed company insights
Polaryx Therapeutics is a late-stage clinical biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, which are rare inherited metabolic diseases. The company aims to address these conditions through innovative drug candidates that include new chemical entities and rep... Read More
